| Solano Primary Care Medical Group | |
|
155 Glen Cove Marina Rd E # 10 Vallejo CA 94591-7284 | |
| (707) 558-8699 | |
| Not Available |
| Full Name | Solano Primary Care Medical Group |
|---|---|
| Speciality | Family Medicine |
| Location | 155 Glen Cove Marina Rd E # 10, Vallejo, California |
| Authorized Official Name and Position | Fred Bayon (MD) |
| Authorized Official Contact | 7075588699 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Solano Primary Care Medical Group 155 Glen Cove Marina Rd E # 10 Vallejo CA 94591-7284 Ph: (707) 558-8699 | Solano Primary Care Medical Group 155 Glen Cove Marina Rd E # 10 Vallejo CA 94591-7284 Ph: (707) 558-8699 |
| NPI Number | 1083763155 |
|---|---|
| Provider Enumeration Date | 01/09/2007 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 3274577606 |
|---|---|
| Medicare Enrollment ID | O20050615001119 |
News Archive
A study appearing today in the New England Journal of Medicine adds to the growing body of evidence supporting continuous renal replacement therapy (CRRT) as the therapy of choice for treatment of acute kidney injury (AKI) patients in the intensive care unit (ICU).
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
Rainbow Biosciences, a division of Rainbow Coral Corp. announced today that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc.
Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.
Last night, five surgeons received the 2017 American College of Surgeons/Pfizer Surgical Humanitarian Awards and Surgical Volunteerism Awards in recognition of their selfless efforts as volunteer surgeons who provide care to medically underserved patients abroad.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083763155 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Paige A Yoshisato |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770586802 PECOS PAC ID: 2961469713 Enrollment ID: I20041214000507 |
News Archive
A study appearing today in the New England Journal of Medicine adds to the growing body of evidence supporting continuous renal replacement therapy (CRRT) as the therapy of choice for treatment of acute kidney injury (AKI) patients in the intensive care unit (ICU).
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
Rainbow Biosciences, a division of Rainbow Coral Corp. announced today that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc.
Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.
Last night, five surgeons received the 2017 American College of Surgeons/Pfizer Surgical Humanitarian Awards and Surgical Volunteerism Awards in recognition of their selfless efforts as volunteer surgeons who provide care to medically underserved patients abroad.
› Verified 5 days ago
| Provider Name | Fred Bayon |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1225031362 PECOS PAC ID: 6507925443 Enrollment ID: I20081113000190 |
News Archive
A study appearing today in the New England Journal of Medicine adds to the growing body of evidence supporting continuous renal replacement therapy (CRRT) as the therapy of choice for treatment of acute kidney injury (AKI) patients in the intensive care unit (ICU).
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
Rainbow Biosciences, a division of Rainbow Coral Corp. announced today that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc.
Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.
Last night, five surgeons received the 2017 American College of Surgeons/Pfizer Surgical Humanitarian Awards and Surgical Volunteerism Awards in recognition of their selfless efforts as volunteer surgeons who provide care to medically underserved patients abroad.
› Verified 5 days ago
News Archive
A study appearing today in the New England Journal of Medicine adds to the growing body of evidence supporting continuous renal replacement therapy (CRRT) as the therapy of choice for treatment of acute kidney injury (AKI) patients in the intensive care unit (ICU).
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
Rainbow Biosciences, a division of Rainbow Coral Corp. announced today that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc.
Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.
Last night, five surgeons received the 2017 American College of Surgeons/Pfizer Surgical Humanitarian Awards and Surgical Volunteerism Awards in recognition of their selfless efforts as volunteer surgeons who provide care to medically underserved patients abroad.
› Verified 5 days ago
California Maritime Academy Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 200 Maritime Academy Dr, Vallejo, CA 94590 Phone: 707-654-1170 Fax: 707-654-1171 | |
Voltaire S. Velarde Md Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 646 Tennessee St, Vallejo, CA 94590 Phone: 707-552-7111 | |
Jaime M. Singzon, M.d., Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 646 Tennessee St, Vallejo, CA 94590 Phone: 707-554-3331 Fax: 707-554-3332 | |
Solano Center Of Excellence Medical Corp Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1760 Tuolumne St, Vallejo, CA 94589 Phone: 707-551-3360 Fax: 707-643-3018 | |
La Clinica De La Raza Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 220 Hospital Dr, Vallejo, CA 94589 Phone: 510-535-2958 | |
Medmek Medical Clinic, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 433 Tuolumne St, Suite, Vallejo, CA 94590 Phone: 510-230-3817 |